Prescription Medicine Study Committee
S0749 is a joint resolution that creates the Prescription Medicine Study Committee to examine ways to reduce the cost of prescription drugs that are considered critical to South Carolina residents. The resolution frames the issue around the burden of chronic disease and the rising cost of medications needed to treat conditions such as diabetes, heart disease, and dementia. It directs the committee to study approaches used in other states, the federal government, and private industry, and to focus on barriers such as pricing structures, supply chains, pharmacy benefit managers, insurers, and pharmaceutical manufacturers.
The committee is also tasked with considering policy options such as bulk purchasing, state-supported distribution models, rebate reforms, and manufacturer transparency requirements. It may gather information from state agencies and engage consumers, providers, and industry stakeholders through hearings or written submissions. The committee must report its findings, recommendations, and any proposed legislation to the General Assembly by December 31, 2026, after which it dissolves unless reauthorized.
Because this is a joint resolution, the bill does not itself change substantive prescription drug law. Instead, it creates a temporary legislative study committee and authorizes it to collect information, evaluate existing cost-reduction models, and recommend future statutory, regulatory, or pilot-program changes. Its practical impact is to place prescription drug affordability, PBM practices, and state purchasing strategies under formal legislative review, with participation from key state agencies, health care organizations, insurers, and a PBM representative.
The overall sentiment reflected in the bill text is strongly supportive of action to address prescription drug affordability. The findings emphasize that access to affordable medicine is essential and that high drug prices burden families, providers, and the state. No committee transcript or vote record was provided, so there is no additional evidence of opposition or divided sentiment in the available context.
The main areas of potential contention are the policy tools the committee may consider, especially reforms involving pharmacy benefit managers, insurer practices, manufacturer transparency, rebate structures, and state-led purchasing or distribution models. Those topics can implicate competing interests among patients, health plans, PBMs, pharmaceutical manufacturers, hospitals, and state benefit programs such as PEBA. The committee’s membership reflects that balance by including both industry and public-sector stakeholders, suggesting the legislature expects debate over which cost-control approaches are feasible and how to reduce prices without harming access, safety, or quality of care.